Pipeline

Our goalsTwo complementary product candidates for colorectal cancer

Pyovita is advancing two complementary preclinical product candidates for colorectal cancer. Both target the protective tumor microenvironment and are based on the same core therapeutic approach, but they use distinct therapeutic formats.

LEAD PROGRAMStandalone therapeutic for colorectal cancer

A novel therapeutic designed to remodel the extracellular matrix surrounding tumors, expose protected cancer cells, and improve access for existing treatments and immune cells.

Development stage: Preclinical

SECOND PROGRAMEngineered bacterial therapy for colorectal cancer

Beneficial bacteria engineered to accumulate within tumors, produce the therapeutic locally, and help remodel the tumor microenvironment. This approach is intended to provide sustained local activity while limiting exposure of healthy tissues.

Development stage: Early preclinical

A shared therapeutic strategy

The two programs address the same fundamental challenge: the protective tumor environment that can restrict drug penetration, shield resistant cancer cells, and suppress effective immune responses.

The standalone program offers a focused path for developing the therapeutic in combination with existing colorectal cancer treatments. The bacterial program adds local production and the tumor-interacting properties of engineered bacteria.

Together, these programs give Pyovita two complementary routes for making colorectal tumors more accessible and responsive to treatment.

About us